Price
$114.77
Decreased by -1.18%
Dollar volume (20D)
772.18 M
ADR%
2.19
Earnings report date
Oct 23, 2025
Shares float
1.24 B
Shares short
19.99 M [1.61%]
Shares outstanding
1.24 B
Market cap
144.11 B
Beta
0.35
Price/earnings
23.04
20D range
108.54 121.83
50D range
104.46 121.83
200D range
84.17 121.83

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with MerusN. V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.

The company was incorporated in 1987 and is headquartered in Foster City, California.

Reported date EPSChange YoY EstimateSurprise
Aug 7, 25 2.01
Increased by 0.00%
1.96
Increased by +2.55%
May 8, 25 1.81
Increased by +237.12%
1.77
Increased by +2.11%
Feb 4, 25 1.90
Increased by +10.47%
1.70
Increased by +11.73%
Nov 6, 24 2.02
Decreased by -11.79%
1.55
Increased by +30.32%
Aug 8, 24 2.01
Increased by +21.08%
1.60
Increased by +25.62%
Apr 25, 24 -1.32
Decreased by -196.35%
-1.49
Increased by +11.41%
Feb 6, 24 1.72
Increased by +2.99%
1.76
Decreased by -2.27%
Nov 7, 23 2.29
Increased by +20.53%
1.92
Increased by +19.27%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 7.08 B
Increased by +1.84%
1.96 B
Increased by +21.44%
Increased by +27.68%
Increased by +19.24%
Mar 31, 25 6.67 B
Decreased by -0.28%
1.31 B
Increased by +131.53%
Increased by +19.72%
Increased by +131.62%
Dec 31, 24 7.57 B
Increased by +6.40%
1.78 B
Increased by +24.77%
Increased by +23.56%
Increased by +17.27%
Sep 30, 24 7.54 B
Increased by +7.02%
1.25 B
Decreased by -42.52%
Increased by +16.61%
Decreased by -46.29%
Jun 30, 24 6.95 B
Increased by +5.36%
1.61 B
Increased by +54.45%
Increased by +23.21%
Increased by +46.59%
Mar 31, 24 6.69 B
Increased by +5.26%
-4.17 B
Decreased by -512.87%
Decreased by -62.37%
Decreased by -492.25%
Dec 31, 23 7.11 B
Decreased by -3.72%
1.43 B
Decreased by -12.87%
Increased by +20.09%
Decreased by -9.50%
Sep 30, 23 7.05 B
Increased by +0.11%
2.18 B
Increased by +21.86%
Increased by +30.92%
Increased by +21.72%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY